Antipsychotic News and Research

RSS

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.

Enrollment complete in ACADIA's pimavanserin Phase III trial for Parkinson's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the completion of enrollment in its ongoing pivotal Phase III trial with pimavanserin in patients with Parkinson's disease psychosis (PDP).

5 Sep 2012

Subthreshold metabolic syndrome common in drug-naïve schizophrenia patients

Around 1 in 10 antipsychotic-naïve Indian patients with schizophrenia meet full criteria for the metabolic syndrome, but a significantly larger proportion have subthreshold metabolic syndrome, researchers report.

4 Sep 2012

Limited evidence supports medical intervention use in adolescents and young adults with autism

Vanderbilt University researchers studying interventions for adolescents and young adults with autism are reporting today that there is insufficient evidence to support findings, good or bad, for the therapies currently used.

28 Aug 2012

Research roundup: Who do patients seek for primary care?; Treating kids with antipsychotics

n order to find out what kind of doctor patients were visiting for primary care service, researchers analyzed the frequency in which patients visited generalists and specialists in 1999 and 2007 by using a nationally representative sample of outpatient visits.

26 Aug 2012

Schizophrenia patients benefit from text message reminders

A text message-based service may help improve medication adherence in patients with schizophrenia, researchers report.

23 Aug 2012

Schizophrenia patients benefit from text message reminders

A text message-based service may help improve medication adherence in patients with schizophrenia, researchers report.

22 Aug 2012

Prenatal antipsychotic exposure linked to reduced neuromotor performance

Infants with prenatal exposure to antipsychotics show significant reductions in neuromotor performance compared with other children, US researchers report.

17 Aug 2012

Health law critically important to women; Expanding Medicaid could spur state education cuts; Misuse of antipsychotics in dementia patients

If we can set aside the political wrangling and focus on the benefits of the Affordable Care Act, what becomes obvious is its critically important impact on women's health. The fact is while women are the primary coordinators of health care for families and comprise the majority of U.S. health-care workers, they also put their own health-care needs behind those of their children. Cost is too often the reason.

13 Aug 2012

Epigenetic factors involved in treatment-resistance to schizophrenia drugs

Researchers at Mount Sinai School of Medicine may have discovered why certain drugs to treat schizophrenia are ineffective in some patients. Published online in Nature Neuroscience, the research will pave the way for a new class of drugs to help treat this devastating mental illness, which impacts one percent of the world's population, 30 percent of whom do not respond to currently available treatments.

13 Aug 2012

Prenatal antipsychotic exposure linked to reduced neuromotor performance

Infants with prenatal exposure to antipsychotics show significant reductions in neuromotor performance compared with other children, US researchers report.

8 Aug 2012

Blood levels of IL-6 protein may also serve as red flag for relapse in schizophrenia patients

Blood levels of a protein that helps regulate inflammation may also serve as a red flag for relapse in some schizophrenia patients, researchers said.

7 Aug 2012

HHS report: Hospitals fall short in meeting error reporting requirements

The government report says the failure to report medical errors hampers providers' ability to identify and fix preventable problems. Meanwhile, new Medicare data shows hospitals are making little progress in reducing preventable readmissions.

21 Jul 2012

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

Johnson & Johnson today announced sales of $16.5 billion for the second quarter of 2012, a decrease of 0.7% as compared to the second quarter of 2011. Operational results increased 3.5% and the negative impact of currency was 4.2%.

17 Jul 2012

Psychotic depression now fulfills the criteria for a valid psychiatric syndrome

The number of studies reporting significant and clinically relevant differences between psychotic depression (PD) and non-PD has increased considerably over the past decades. This summary of the current evidence suggests that PD now fulfils the criteria for a valid psychiatric syndrome.

14 Jul 2012

Antipsychotic use in pregnancy should be closely monitored

Use of any type of antipsychotic during pregnancy increases the risk for women developing gestational diabetes, show Swedish study results that also indicate a link between antipsychotics and a risk for giving birth to a small for gestational age infant.

13 Jul 2012

Gestational diabetes may be more likely with antipsychotic use

Women who take antipsychotic medication during pregnancy may be at an increased risk for developing gestational diabetes, report researchers.

10 Jul 2012

ACADI’s pimavanserin may have therapeutic benefits in treatment of ADP

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced results of preclinical studies, which suggest that pimavanserin, ACADIA's proprietary product candidate currently in Phase III development for Parkinson's disease psychosis, also may have therapeutic benefits in the treatment of Alzheimer's disease psychosis (ADP).

10 Jul 2012

Treatment of Schizophrenia receives notice of intention to grant a European patent

BioLineRx (NASDAQ:BLRX)(TASE:BLRX), a biopharmaceutical development company, announced today that it has received from the European Patent Office a notice of intention to grant a European patent claiming the salt of BL-1020, a first-in-class orally available treatment for schizophrenia.

9 Jul 2012

Oxytocin levels linked to medication dose, symptoms in schizophrenia

Higher doses of second-generation antipsychotics and more severe negative symptoms are associated with lower levels of oxytocin in cerebrospinal fluid among patients with schizophrenia, researchers report.

29 Jun 2012

Mass. nursing homes miss out on federal grant to curb inappropriate sedative use

Nursing Homes In Massachusetts will not get a federal grant to help them drive down use of antipsychotic drugs. In Kansas, officials launched a campaign to encourage reporting of elder abuse.

19 Jun 2012